Share-based Payment Arrangement, Expense in USD of Accelerate Diagnostics, Inc from Q2 2015 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Accelerate Diagnostics, Inc quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q2 2015 to Q4 2024.
  • Accelerate Diagnostics, Inc Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2024 was $964,000, a 29% decline year-over-year.
  • Accelerate Diagnostics, Inc Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2024 was $4,382,000, a 19% decline year-over-year.
  • Accelerate Diagnostics, Inc annual Share-based Payment Arrangement, Expense for 2024 was $4,382,000, a 19% decline from 2023.
  • Accelerate Diagnostics, Inc annual Share-based Payment Arrangement, Expense for 2023 was $5,387,000, a 49% decline from 2022.
  • Accelerate Diagnostics, Inc annual Share-based Payment Arrangement, Expense for 2022 was $10,625,000, a 52% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Accelerate Diagnostics, Inc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $4,382,000 $964,000 -$400,000 -29% 01 Oct 2024 31 Dec 2024 10-K 21 Mar 2025 2024 FY
Q3 2024 $4,782,000 $1,155,000 -$660,000 -36% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $5,442,000 $966,000 -$687,000 -42% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $6,129,000 $1,297,000 +$742,000 +134% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $5,387,000 $1,364,000 -$1,082,000 -44% 01 Oct 2023 31 Dec 2023 10-K 21 Mar 2025 2024 FY
Q3 2023 $6,469,000 $1,815,000 +$586,000 +48% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $5,883,000 $1,653,000 -$2,318,000 -58% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $8,201,000 $555,000 -$2,424,000 -81% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $10,625,000 $2,446,000 -$543,000 -18% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $11,168,000 $1,229,000 -$2,400,000 -66% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $13,568,000 $3,971,000 -$2,619,000 -40% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $16,187,000 $2,979,000 -$5,860,000 -66% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $22,047,000 $2,989,000 -$1,184,000 -28% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2024 2023 FY
Q3 2021 $23,231,000 $3,629,000 -$1,047,000 -22% 01 Jul 2021 30 Sep 2021 10-Q/A 03 Mar 2023 2022 Q3
Q2 2021 $24,278,000 $6,590,000 +$3,174,000 +93% 01 Apr 2021 30 Jun 2021 10-Q/A 03 Mar 2023 2022 Q2
Q1 2021 $21,104,000 $8,839,000 +$4,640,000 +111% 01 Jan 2021 31 Mar 2021 10-Q/A 03 Mar 2023 2022 Q1
Q4 2020 $16,464,000 $4,173,000 +$964,000 +30% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2023 2022 FY
Q3 2020 $15,500,000 $4,676,000 +$1,545,000 +49% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $13,955,000 $3,416,000 +$535,000 +19% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $13,420,000 $4,199,000 +$802,000 +24% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $12,618,000 $3,209,000 +$1,263,000 +65% 01 Oct 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
Q3 2019 $11,355,000 $3,131,000 -$334,000 -9.6% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $11,689,000 $2,881,000 -$528,000 -15% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $12,217,000 $3,397,000 -$2,205,000 -39% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $14,422,000 $1,946,000 -$1,017,000 -34% 01 Oct 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
Q3 2018 $15,439,000 $3,465,000 -$55,000 -1.6% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $15,494,000 $3,409,000 -$826,000 -20% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $16,320,000 $5,602,000 +$2,387,000 +74% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $13,933,000 $2,963,000 +$779,000 +36% 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
Q3 2017 $13,154,000 $3,520,000 +$850,000 +32% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $12,304,000 $4,235,000 +$2,000,000 +89% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $10,304,000 $3,215,000 +$1,529,000 +91% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $8,775,000 $2,184,000 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
Q3 2016 $2,670,000 +$860,000 +48% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $2,235,000 -$293,000 -12% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $1,686,000 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q3 2015 $1,810,000 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $2,528,000 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2

Accelerate Diagnostics, Inc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,382,000 -$1,005,000 -19% 01 Jan 2024 31 Dec 2024 10-K 21 Mar 2025 2024 FY
2023 $5,387,000 -$5,238,000 -49% 01 Jan 2023 31 Dec 2023 10-K 21 Mar 2025 2024 FY
2022 $10,625,000 -$11,422,000 -52% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $22,047,000 +$5,583,000 +34% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2024 2023 FY
2020 $16,464,000 +$3,846,000 +30% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2023 2022 FY
2019 $12,618,000 -$1,804,000 -13% 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
2018 $14,422,000 +$489,000 +3.5% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
2017 $13,933,000 +$5,158,000 +59% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $8,775,000 +$387,000 +4.6% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2015 $8,388,000 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.